Hancock Jaffe Laboratories Inc P/E Adelante
¿Qué es el P/E Adelante de Hancock Jaffe Laboratories Inc?
El P/E Adelante de Hancock Jaffe Laboratories Inc es -6.70
¿Cuál es la definición de P/E Adelante?
La relación precio a futuro es la relación entre el precio de las acciones de una empresa y las ganancias por acción estimadas de la compañía para los próximos doce meses.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
P/E Adelante de compañías en Sector Health Care en NASDAQ en comparadas con Hancock Jaffe Laboratories Inc
¿Qué hace Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Empresas con p/e adelante similar a Hancock Jaffe Laboratories Inc
- Focus Inc tiene P/E Adelante de -6.86
- Zevra Therapeutics Inc tiene P/E Adelante de -6.83
- RiceBran Technologies tiene P/E Adelante de -6.78
- Digirad Corp tiene P/E Adelante de -6.77
- Cynata Therapeutics tiene P/E Adelante de -6.77
- Mustang Bio Inc tiene P/E Adelante de -6.76
- Hancock Jaffe Laboratories Inc tiene P/E Adelante de -6.70
- Aqua Metals Inc tiene P/E Adelante de -6.67
- Biocryst Pharmaceuticals tiene P/E Adelante de -6.67
- OptiNose Inc tiene P/E Adelante de -6.64
- Citius Pharmaceuticals Inc tiene P/E Adelante de -6.64
- Replimune Inc tiene P/E Adelante de -6.61
- Celcuity Inc tiene P/E Adelante de -6.59